Ryan Brimeyer, DO
Pulmonary Disease · West Des Moines, IANPI 1245435379
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,015 of the $8,627 with a category attached, or 69.7%. Intuitive Surgical accounts for 84.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $7,129 and has fallen 98.4% since, to $116 in 2025.
Across 19 payments — averaging $454.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Veran Medical Technologies, Inc.$1K
- Sanofi$122
- Itamar Medical Inc$53
- KARL Storz Endoscopy-america$47
- Boehringer Ingelheim$15
Across 117 payments — averaging $3432.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$149K
- Sanofi US Services Inc.$97K
- Boehringer Ingelheim$84K
- Astrazeneca AB$57K
- Boehringer Ingelheim International GmbH$14K
- Astrazeneca UK Limited$1K
What the payments were for
- Travel & lodging$1,81521%
- Food & beverage$7989%
- Education$6,01570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $7,328 |
| Veran Medical Technologies, Inc. | 4 | $1,063 |
| Sanofi | 1 | $122 |
| Itamar Medical Inc | 1 | $53 |
| KARL Storz Endoscopy-america | 1 | $47 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,176
- ION$3,000
- Spin$1,010
- DUPIXENT$122
How this compares
$8,627 in reported general payments places this provider in the 80th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 512 | $378,880 |
| Breo ElliptaFluticasone/Vilanterol | 327 | $151,331 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 135 | $80,713 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 75 | $46,673 |
| Spiriva HandihalerTiotropium Bromide | 56 | $45,891 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $34,565 |
| Advair HfaFluticasone Propion/Salmeterol | 61 | $32,074 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 35 | $28,882 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 202 | $24,231 |
| SymbicortBudesonide/Formoterol Fumarate | 78 | $22,621 |
| Spiriva RespimatTiotropium Bromide | 35 | $21,158 |
| Arnuity ElliptaFluticasone Furoate | 69 | $19,269 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $13,847 |
| DuleraMometasone/Formoterol | 21 | $11,415 |
| Ventolin HfaAlbuterol Sulfate | 163 | $10,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $15 | $96,712145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in West Des Moines
- Dustin McCannWest Des Moines$67K
- Matthew TrumpWest Des Moines$41K
- James MallenWest Des Moines$16K
- Samantha Danielson-JonesWest Des Moines$11K
- Amerlon EnriquezWest Des Moines$7K
- Daniel DodgeWest Des Moines$6K
- Ryan MertensWest Des Moines$6K
- John ScottWest Des Moines$3K
- Katrina GuestWest Des Moines$1K
- Gregory HicklinWest Des Moines$422
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.